| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,666 | -20,102 |
| Depreciation and amortization | 263 | 135 |
| Non-cash operating lease cost | 280 | 184 |
| Impairment of right-of-use assets | 1,411 | - |
| (gain) loss on fair value remeasurement of contingent consideration | 4,659 | -174 |
| Amortization of debt discount and other non-cash interest | 475 | 359 |
| Stock-based compensation | 6,594 | 4,550 |
| Prepaid expenses and other current assets | 1,562 | 105 |
| Other long-term assets | - | 7 |
| Accounts payable | 289 | 30 |
| Accrued expenses and other current liabilities | -2,580 | -1,596 |
| Lease liabilities and other long-term liabilities | -280 | -180 |
| Net cash used in operating activities | -27,435 | -16,558 |
| Purchases of property and equipment and other assets | 15 | 16 |
| Net cash used in investing activities | -15 | -16 |
| Payment of principal and payment fee on debt | 2,500 | 2,500 |
| Payment of issuance costs from issuance of common stock and series i preferred stock | 120 | 120 |
| Payment of principal on finance lease | 88 | 58 |
| Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan | 73 | 13 |
| Net cash (used in) provided by financing activities | -2,635 | -2,665 |
| Net (decrease) increase in cash and cash equivalents | -30,085 | -19,239 |
| Cash and cash equivalents at beginning of period | 51,181 | - |
| Cash and cash equivalents at end of period | 21,096 | - |
KALA BIO, Inc. (KALA)
KALA BIO, Inc. (KALA)